Moderna unveiled plans for a research and manufacturing center in the UK.

O

The American pharmaceutical giant Moderna will open a new research and manufacturing center in the UK.

It is hoped that the move will guarantee British patients faster access to new vaccines and treatments.

The new mRNA Innovation and Technology Center will develop vaccines for a wide range of respiratory diseases, including the Covid vaccine, which can protect against many types.

Meanwhile, a large-scale MRNA vaccine manufacturing center will develop new and existing drugs and create new jobs, officials said.

Construction is expected to begin earlier this year, with the first MRNA vaccine to be manufactured in the UK in 2025.

NHS patients will benefit from scientific breakthroughs and state-of-the-art manufacturing centers will ensure our ability to respond to the next epidemic by ensuring that we will be able to rapidly develop vaccines on our shores.

Officials said the agreement would give NHS patients access to clinical trials of the firm’s vaccine as well as access to “state-of-the-art” vaccines.

Moderna’s CoVID-19 vaccine uses messenger RNA (mRNA) – these vaccines teach body cells how to make a protein that stimulates the immune response.

It is hoped that this technology will be used to treat a number of diseases, including cancer, dementia, flu and heart disease.

The ministers said a new strategic partnership with the firm would help the UK provide “future evidence” against future health risks.

Prime Minister Boris Johnson said: “We are bringing supercharged home-made vaccines to our shores.

“I want the UK to be the brightest and best in research and technology, create more jobs and secure our economic future.

“Our investment will guarantee jobs in the arsenal against some of the most difficult viruses out there, which will put us at the forefront of the fight against future threats.”

“We’ve all seen what vaccines can do, and today’s partnership brings us one step closer to finding a cure for some of the most devastating diseases.”

Health Secretary Sajid Javed added: “Our new partnership with Moderna will strengthen the UK’s position as a science superpower, significantly boosting the economy and creating jobs – and It has the potential to unleash the next generation of modern vaccines to fight diseases such as cod, seasonal flu and respiratory syncytial virus (RSV).

“mRNA is truly a transformative technology and we have seen its life-saving power during epidemics.

“Thanks to this new agreement, NHS patients will benefit from scientific breakthroughs and the state-of-the-art manufacturing center will increase our ability to respond to the next epidemic by ensuring that we rapidly develop vaccines on our shores.” Are able to. “

And Stephane Bancel, Moderna’s chief executive, said: “We are excited to continue our collaboration with the UK Government and the Vaccine Task Force with this new mRNA Innovation and Technology Center in the UK.

“We are committed to global public health, and as we expand internationally, we are pleased to bring local mRNA manufacturing to the UK.

“We look forward to establishing our R&D (research and development) activities and capabilities in the country.”

Sir Patrick Valence, the government’s chief scientific adviser, said the announcement was “great news for the UK’s R&D activities and future capabilities”.

He added: “Rapid vaccines were very important in the response to the epidemic.

“It will be important to develop the next generation of mRNA vaccines to enhance our ability to prevent and respond to a wide range of respiratory diseases in the future.”